print button

Metabolic Disease

Cedars-Sinai has already set many milestones in the treatment of metabolic illnesses, including:

  • Identifying a genetic marker for inflammatory bowel disease that indicates whether the disease will be aggressive or benign
  • Discovering a new protein that regulates intestinal inflammation in Crohn’s disease
  • Developing new drugs for the treatment of pituitary tumors

Make a Gift

Mark Pimentel, MD

Mark Pimentel, MD, is Director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai.

Support Cedars-Sinai